Gemifloxacin is the updated fluoroquinolone and promptly carries the highest efficacy over any other drug in respiratory tract infections or pneumonia. It has 5 folds more affinity than ciprofloxacin in binding and inhibiting bacterial topisomerase-IV and thus ensures less microbial resistance than ciprofloxacin. All clinical trials have established gemifloxacin as a potent and effective antibiotic in RTI. Its safety margin is almost equal to ciprofloxacin.
But I wonder, the market shows gemifloxacin as a potential negative growth medicine for a long time.
No gemifloxacin in Belgium.
I cannot speak for other countries, but in Belgium most LRTIs are still adequately being managed with (high-dose) (amino)penicillins (e.g. amoxicillin), especially in primary care.
In case of allergy, the proposed FQ is moxifloxacin.
Kind regards
well, gemifloxacin is restricted in many countries, but for ENT infection and Community acquired pneumonia, gemifloxacin is the best choice.
Gemifloxacin is given for the treatment of Acute exacerbation of chronic bronchitis (AECB) and is compaarable to other known drugs in safety and efficacy in India.
yeah, gemifloxacin is mainly indicated for only two infections: 1) Acute Exacerbation of Chronic Bronchitis (AECB) & 2) Community Acquired Pneumonia (CAP).
I think cost is one of the major factor concerning physicians choice to prescribe this drug in general patients.
- Badges
- Science topic
- Similar topics
- Biological Science
- Molecular Biology
- Biomolecules
- Nucleic Acids
- DNA